Evidence map›Paper›PMID 41906184›Full record

Trial reportThe International journal of eating disorders2026

Cannabidiol in Anorexia Nervosa: A Double-Blind Randomized Placebo Controlled Pilot Study to Test Safety, Pharmacokinetics, and Symptom Change.

Neha Sahota, David J Grelotti, Tyler Nguyen, Walter H Kaye, Skylar Swindle, Raymond Suhandynata, Spencer Seely, Megan E Shott, Guido K W Frank

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The International journal of eating disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04878627 (The Role of Cannabidiol in Regulating Meal Time Anxiety in Anorexia Nervous), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04878627 early_phase1active not recruitingnot on this map

The Role of Cannabidiol in Regulating Meal Time Anxiety in Anorexia Nervous: Safety, Tolerability and Pharmacokinetics

TypeinterventionalSponsorUniversity of California, San DiegoRan2022 to 2026Enrolled40ConditionsAnorexia NervosaArmsCannabidiol, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Neha SahotaKeck School of Medicine of the University of Southern California, Los Angeles, USA.ORCID https://orcid.org/0009-0001-6661-5169
David J GrelottiDepartment of Psychiatry, University of California San Diego, San Diego, USA.ORCID https://orcid.org/0000-0002-9044-1314
Tyler NguyenDepartment of Psychiatry, University of California San Diego, San Diego, USA.ORCID https://orcid.org/0009-0006-3689-8846
Walter H KayeDepartment of Psychiatry, University of California San Diego, San Diego, USA.ORCID https://orcid.org/0000-0002-4478-4906
Skylar SwindleDepartment of Psychiatry, University of California San Diego, San Diego, USA.ORCID https://orcid.org/0000-0003-2322-0447
Raymond SuhandynataSkaggs School of Pharmacy & Pharmaceutical Sciences, University of California San Diego, San Diego, USA.ORCID https://orcid.org/0000-0002-4767-7639
Spencer SeelySkaggs School of Pharmacy & Pharmaceutical Sciences, University of California San Diego, San Diego, USA.ORCID https://orcid.org/0000-0002-1647-8872
Megan E ShottDepartment of Psychiatry, University of California San Diego, San Diego, USA.ORCID https://orcid.org/0009-0007-9763-514X
Guido K W FrankDepartment of Psychiatry, University of California San Diego, San Diego, USA.ORCID https://orcid.org/0000-0002-6590-3441

Funding

Center for Medicinal Cannabis Research, University of California, San Diego P64 #x02010;01 #x02010;005
6 · The paper itself

Abstract

objectiveAnorexia nervosa (AN) is a severe psychiatric disorder marked by an intense fear of gaining weight and persistent body dissatisfaction, both during periods of underweight and after weight restoration. The endocannabinoid system may offer therapeutic benefits, particularly in reducing anxiety. This randomized controlled trial of cannabidiol (CBD) investigated safety, tolerability, pharmacokinetics, and symptomatic improvement in AN.

methodIn a double-blind design, women with AN or Atypical AN were randomized to receive CBD (n = 16) or placebo (n = 16) over 21 days. The dose was up-titrated weekly from 1.25 mg/kg twice daily to a maximum of 6.25 mg/kg twice daily, while assessing CBD and metabolite levels, liver function, and severity of eating disorder, depression, and anxiety symptoms.

resultsAge at baseline was similar between the CBD and placebo group (22.9 ± 2.8 years vs. 22.5 ± 3.5 years), as was body mass index (BMI, kg/m DISCUSSION: This study suggests that CBD is well tolerated in individuals with AN. Furthermore, indication of better weight recovery and improvement of eating disorder specific symptoms in the CBD group suggest treatment effects of CBD in AN. The study was, however, constrained by its small sample size and limited duration and requires replication in a larger sample.

trial registrationClinicalTrials.gov identifier NCT04878627.

Indexed as

Anorexia NervosaCannabidiolAdolescentAdultDouble-Blind MethodFemaleHumansPilot ProjectsTreatment OutcomeYoung AdultCannabidiolanorexia nervosacannabidiolcannabisCBDpsychopharmacologytreatmentweight gain

Identifiers

PMID41906184
PMCPMC13326766

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.